Insider Selling: REGENXBIO (NASDAQ:RGNX) Insider Sells 19,608 Shares of Stock

REGENXBIO Inc. (NASDAQ:RGNX) insider Steve Pakola sold 19,608 shares of the business’s stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $11.04, for a total value of $216,472.32. Following the sale, the insider directly owned 213,009 shares of the company’s stock, valued at $2,351,619.36. This represents a 8.43% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Steve Pakola also recently made the following trade(s):

• On Wednesday, July 1st, Steve Pakola sold 36,725 shares of REGENXBIO stock. The stock was sold at an average price of $12.86, for a total value of $472,283.50.
• On Monday, May 11th, Steve Pakola sold 15,309 shares of REGENXBIO stock. The shares were sold at an average price of $11.02, for a total value of $168,705.18.

REGENXBIO Trading Up 9.3%

NASDAQ RGNX traded up $1.11 on Wednesday, reaching $13.09. 4,456,460 shares of the stock were exchanged, compared to its average volume of 2,291,967. REGENXBIO Inc. has a one year low of $5.45 and a one year high of $16.19. The firm has a market capitalization of $676.75 million, a PE ratio of -2.34 and a beta of 0.90. The company’s 50-day simple moving average is $8.12 and its two-hundred day simple moving average is $9.91.

REGENXBIO (NASDAQ:RGNX) last posted its quarterly earnings results on Thursday, May 14th. The biotechnology company reported ($1.72) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.36) by ($0.36). The firm had revenue of $6.39 million during the quarter, compared to the consensus estimate of $25.84 million. REGENXBIO had a negative return on equity of 232.50% and a negative net margin of 330.23%. Sell-side analysts forecast that REGENXBIO Inc. will post -3.69 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on RGNX shares. Bank of America cut their price target on REGENXBIO from $25.00 to $14.00 and set a “buy” rating for the company in a research note on Friday, May 15th. Barclays dropped their price objective on REGENXBIO from $37.00 to $12.00 and set an “overweight” rating for the company in a research note on Friday, May 15th. HC Wainwright reiterated a “buy” rating and set a $26.00 target price on shares of REGENXBIO in a research report on Wednesday. Weiss Ratings reissued a “sell (e+)” rating on shares of REGENXBIO in a report on Monday, June 8th. Finally, Morgan Stanley set a $16.00 price target on REGENXBIO in a research note on Friday, May 15th. Ten equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, REGENXBIO currently has an average rating of “Moderate Buy” and a consensus price target of $23.82.

Institutional Investors Weigh In On REGENXBIO

Several large investors have recently added to or reduced their stakes in the stock. Deutsche Bank AG lifted its stake in shares of REGENXBIO by 0.8% in the 4th quarter. Deutsche Bank AG now owns 192,582 shares of the biotechnology company’s stock valued at $2,773,000 after purchasing an additional 1,527 shares during the last quarter. Captrust Financial Advisors increased its position in REGENXBIO by 13.2% during the fourth quarter. Captrust Financial Advisors now owns 15,228 shares of the biotechnology company’s stock valued at $219,000 after acquiring an additional 1,781 shares during the last quarter. Diversified Trust Co boosted its stake in shares of REGENXBIO by 15.9% during the 1st quarter. Diversified Trust Co now owns 15,499 shares of the biotechnology company’s stock worth $130,000 after purchasing an additional 2,121 shares during the period. Intech Investment Management LLC lifted its stake in REGENXBIO by 12.2% in the fourth quarter. Intech Investment Management LLC now owns 21,367 shares of the biotechnology company’s stock worth $308,000 after purchasing an additional 2,327 shares during the last quarter. Finally, Focus Partners Advisor Solutions LLC lifted its stake in shares of REGENXBIO by 24.0% during the 4th quarter. Focus Partners Advisor Solutions LLC now owns 12,676 shares of the biotechnology company’s stock worth $183,000 after acquiring an additional 2,455 shares during the last quarter. 88.08% of the stock is owned by institutional investors.

REGENXBIO Company Profile

REGENXBIO Inc is a clinical?stage biotechnology company specializing in the development of gene therapies using its proprietary NAV® AAV (adeno?associated virus) platform. The company engineers next?generation AAV vectors designed to deliver functional genes to targeted cells, aiming to address a range of rare genetic diseases and ocular, metabolic and neurologic disorders. REGENXBIO’s pipeline features several product candidates in various stages of preclinical and clinical development, including RGX-314 for wet age?related macular degeneration, RGX-121 for mucopolysaccharidosis II (Hunter syndrome) and RGX-121 for other rare lysosomal storage diseases.

In addition to its internally funded programs, REGENXBIO has established partnerships with major biopharmaceutical companies to advance its NAV technology.